CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Planning for retirement at the right age is crucial for financial security. Discover how to choose the best age to start your retirement plan.
26,113 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Bloom Energy and Plug Power are leading the move toward cleaner power. This guide breaks down their business models, ...
Two prominent analysts lifted price targets on Newell Brands, sparking a rally where the stock raced higher. This art...
A high-profile insider move in KE Holdings has prompted questions about BEKE stock and China’s housing market. This a...
A Huron Consulting Group director recently sold a sizable block of shares in a single open-market trade. This article...
Dynatrace stock plummeted today after earnings beat but soft guidance signaled a cautious path ahead. This article br...
TJX delivered a solid quarter, lifting confidence in a consumer-driven recovery. This analysis dives into whether com...
A clear, investor-focused guide to the IMSR 2025 Earnings Transcript. Learn what the numbers mean for the company’s p...
When a senior vice president sells stock, it can spark questions about a company's direction. This guide explains wha...
A high-profile insider sale can spark questions about a company’s future. This article breaks down the HeartFlow CEO'...
A prominent Canadian investment firm has disclosed a new stake in Boyd Group Services, highlighting growing interest ...
As biotech earnings season unfolds, Precigen (PGEN) 2025 earnings take center stage. This guide breaks down what to m...